{"id":"W2951994857","doi":"10.1002/hon.52_2629","title":"FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Capital District Health Authority","funders":"Università degli Studi di Perugia; Hospital de Clínicas de Porto Alegre; Monash University; F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Minimal residual disease; Obinutuzumab; Hazard ratio; Clinical endpoint; Population; Surrogate endpoint; Oncology; Venetoclax; Progression-free survival; Confidence interval; Surgery; Chronic lymphocytic leukemia; Randomized controlled trial; Bone marrow; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002063151,0.0002038936,0.000672265,0.00009414181,0.00005218883,0.00002224654,0.00006964411,0.0002366234,0.00009018316],"category_scores_gemma":[0.0003979164,0.0001371807,0.00002656348,0.0001406383,0.0004593232,0.0001139824,0.0001533167,0.000278621,0.00002061598],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01076722,"about_ca_system_score_gemma":0.006457402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003480812,"about_ca_topic_score_gemma":0.000179025,"domain_scores_codex":[0.9982436,0.0002177211,0.0003485281,0.0004782594,0.000282565,0.000429327],"domain_scores_gemma":[0.9986765,0.0005926122,0.0001180039,0.0002392363,0.00009517236,0.0002784892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03800087,0.0005790634,0.9475716,0.001898992,0.0001746398,0.002212529,0.001601721,0.00007512856,0.0005014146,0.00253694,0.001271445,0.003575636],"study_design_scores_gemma":[0.06327177,0.01085954,0.9082426,0.0003144816,0.0001327173,0.0003807271,0.0003251881,0.01458247,0.0003624656,0.0004270184,0.0007367295,0.0003642805],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972025,0.0003407798,0.000003372804,0.0003424906,0.00003905774,0.001441052,0.00001343379,0.00004445594,0.0005728288],"genre_scores_gemma":[0.9989511,0.00006881585,0.0002974967,0.0001978213,0.00002888395,0.00008288411,0.00007875223,0.0000157232,0.0002784953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03932901,"threshold_uncertainty_score":0.9991751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314273874397396,"score_gpt":0.2757265332305638,"score_spread":0.2625837944865899,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}